Proteome Sciences Inks Deal with Eisai for First Commercial Use of Alzheimer's Biomarker Panel
February 04, 2011
Proteome Sciences Inks Deal with Eisai for First Commercial Use of Alzheimer's Biomarker Panel
The agreement calls for Proteome Sciences to quantify plasma levels of the nine proteins in its AD-TMT-SRM panel, which uses multiple-reaction-monitoring mass spectrometry and the company's Tandem Mass Tagging technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Proteome Sciences Signs Contract with Takeda for Protein Biomarker Research
April 1, 2011 / ProteoMonitor - Proteome Sciences and Icon Collaborate on Mass Spec Assays for Pharma Biomarker Development
November 19, 2010 / ProteoMonitor - Taking Aim at Clinical Oncology Market, Proteome Sciences Developing SRM-MS Assay for ER Status
July 22, 2011 / ProteoMonitor - Gothenburg Scientists ID Tyr10-Glycosylated A-beta as Potential Alzheimer's Biomarker
July 15, 2011 / ProteoMonitor - Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor